

Muscle weakness associated with *CAV1* gene mutation: Clinical insights from a vietnamese case

Abstract

Congenital generalized lipodystrophy with *CAV1* variants is a group of conditions characterized by abnormal adipose tissue distribution, including complete or partial loss of adipose tissue or accumulation in internal organs. In males, proximal muscle weakness is commonly associated with Duchenne muscular dystrophy or limb-girdle muscular dystrophy. Here, we present a case of proximal muscle weakness linked to a mutation in the *CAV1* gene. A 34-year-old male patient exhibited symptoms consistent with Duchenne/Trendelenburg syndrome, characterized by irregular coordination of the shoulders and pelvic bones, resulting in a labored gait and challenges in hip, shoulder, and hand joint movements. Clinical Exome Sequencing, along with subsequent Sanger sequencing, was performed and revealed that the patient had a heterozygous in-frame deletion in the *CAV1* gene (NM_001753.5: c.87_89del) (NP_001744.2:p.Asn29del). This variant had not been previously reported. Additionally, his 3-year-old daughter, who suffered from a similar disorder when he was a small child, had a similar genotype. This is the first reported case of autosomal dominant *CAV1*-associated muscle weakness combined with congenital generalized lipodystrophy in Vietnam.

Tam Thi Minh Mai^{2,4}; Huu Cong Nguyen^{1,2}; Anh Hong Vu^{1,2};
Trung Cong Nguyen^{1,3}; Ha Thi Vu^{1,3*}

¹E Hospital, 89 Tran Cung, Cau Giay, Hanoi, Vietnam.

²VNU University of Medicine and Pharmacy, 114 Xuan Thuy, Hanoi, Vietnam.

³Hanoi Medical University, No1, Ton That Tung, Dong Da, Hanoi, Vietnam.

⁴Tam Anh Hospital, 108 Hoang Nhu Tiep, Long bien, Hanoi, Vietnam.

*Corresponding author: Ha Vu Thi

Department of Medical Biology and Genetics, Hanoi Medical University, No1, Ton That Tung, Dong Da, Hanoi, Vietnam.

Email: vuthiha@hmu.edu.vn

Received: Sep 25, 2025; Accepted: Oct 23, 2025;

Published: Oct 30, 2025

Citation: Mai TTM, Nguyen HC, Vu AH, Nguyen TC, Ha Vu T. Muscle weakness associated with *CAV1* gene mutation: Clinical insights from a vietnamese case. *Ann Case Rep Med Images*. 2025; 2(2): 1045.

Keywords: Total/partial body lipodystrophy; *CAV1* gene mutation; Duchenne/Trendelenburg signs; Muscle weakness.

Introduction

CAV1 (Caveolin 1) is a protein-coding gene responsible for encoding caveolin-1 protein, which was found within the caveolae microdomains of the plasma membrane and plays crucial roles in various signaling pathways. Furthermore, caveolin-1 is present in lipid droplets of adipocytes. Pathogenic variants in *CAV1*, whether heterozygous or homozygous, are related to rare and diverse disorders such as pulmonary arterial hypertension, neonatal progeroid syndrome, and congenital generalized lipodystrophy [1].

Congenital Generalized Lipodystrophy (CGL), also known as Berardinelli-Seip syndrome, is a rare condition characterized by virtually absent fatty tissue. Fat loss is usually evident either at birth or within the first year of life, although some patients may be diagnosed later. Patients exhibit a lack of subcutaneous

fat but may have enlarged livers and protruding abdomens in infancy. It is typically inherited in an autosomal recessive manner, depending on the causative gene: *AGPAT2*, *BSCL2*, *CAV1*, or *PTRF* [2-4]. Congenital generalized lipodystrophy related to the *CAV1* gene may present with short stature, vitamin D resistance, hypocalcemia, and magnesium deficiency [5]. A heterozygous frameshift mutation of the *CAV1* gene associated with atypical partial lipodystrophy and hypertriglyceridemia has been reported [6,7]. Another study found a heterozygous *CAV1* mutation identified by exome sequencing associated with a novel neonatal-onset lipodystrophy syndrome [8]. In this study, we report a rare case of a heterozygous in-frame deletion of the *CAV1* gene associated with muscle weakness and congenital generalized lipodystrophy, with detailed clinical characterization, genetic analysis, and autosomal dominant inheritance.

Case history/ examination

A 34-year-old male patient has been experiencing a limp gait, difficulty walking upstairs, or standing up at 3-5 years. These symptoms have been progressively worsening. There was no intellectual disability. He came to our attention with a petite stature, measuring 141.2 cm in height and weighing 34 kg, with a body mass index of 17.6. His gait is cumbersome, indicative of Duchenne/Trendelenburg syndrome (Figure 1), with deformed elbows, flexed wrists, and clenched fists when extended. His overall bone density was severely low, with a T-score of -5.4, and he had a vitamin D deficiency of 17.1 ng/ml. His blood test showed a mild increase in triglycerides (2.78 mmol/L), total cholesterol (6.34 mmol/L), and LDL-C (4.04 mmol/L). Abdominal ultrasonography revealed hepatic steatosis but otherwise normal viscera. Whole-body fat mass assessed by the DEXA method shows no subcutaneous or visceral fat. X-ray images of the patient show slender humerus bones and deformed elbow joints, with normal hip joint and ribs cartilage calcification (Table 1).



Figure 1: The Duchenne/Trendelenburg sign of the patient.

Table 1: Clinical and testing results of the patient.

Clinical characteristics and testing results	Result	Reference range
Body mass index (kg/m ²)	Underweight (BMI=17.6)	18.5-24.9
Lipodystrophy onset	Early infancy	
Squat	Failed to perform	
Proximal muscle weakness	Positive tabouret sign	
The Duchenne de Boulogne sign	Positive sign	
The Trendelenburg sign	Positive sign	
The Duchenne/Trendelenburg sign	(+)	
Flexor tendon shortening	(+)	
X-ray: Slender humerus bones and elbow joints deformity	(+)	
Osteoporosis (DEXA scan test) bone mineral density at lumbar spine T-score	T-score: - 5.4	>-1
No subcutaneous or visceral fat (DEXA)	0.0	
Glucose	5.02 mmol/L	4.1-5.9 mmol/L
Cholesterol	6.34 mmol/L	<5.2 mmol/L
Triglyceride	2.78 mmol/L	<1.7 mmol/L
High density lipoprotein cholesterol	1.04 mmol/L	>0.9 mmol/L
Low density lipoprotein cholesterol	4.04 mmol/L	<3.4 mmol/L
25(OH)Vitamin D (D3)	17.6 ng/mL	>30 ng/mL
Creatinine kinase	84.9 U/L	30-170 U/L
Total calcium	2.40 mmol/L	2.1-2.6 mmol/L
Ionized calcium	1.20 mmol/L	1.17-1.29 mmol/L

His father also had a petite stature and showed signs of muscle weakness; he passed away without a clear diagnosis. His 3-year-old daughter also exhibits muscle weakness similar to his own during childhood. Other family members, such as his mother, sister, and wife, are all normal.

A peripheral blood sample was taken from the patient for Clinical Exome Sequencing. The result of the genetic analysis showed that the patient had a heterozygous in-frame deletion of the *CAV1* gene (NM_001753.5:c.87_89del) (NP_001744.2:p. Asn29del). This variant was searched using in silico tools and public domain libraries (ClinVar, gnomAD, HGMD) to confirm whether it had been previously reported. Based on this process, we confirmed that this variant had not been previously

reported in any literature or clinical variant databases. Sanger sequencing revealed that his 3-year-old daughter, who suffers from the same disorder as the patient did during his childhood, had a similar genotype. Unfortunately, we don't have the genotype of his father, who had similar symptoms. Other members of his family, including his mother, sister, and wife, have normal genotypes according to Sanger sequencing results (Figure 2) and normal phenotypes.

Family pedigree showing the dominant inheritance of the *CAV1* variant in the proband (II.3, indicated by arrow) and his daughter (III.3), both diagnosed with *CAV1*. His father who has died with symptoms of muscular but non-diagnosis. His mother (I.2), his wife (II.4), his older sister (II.2) are also shown no mutation.




Figure 2: The patient's family pedigree (A) and Sanger's sequencing result (B).

Differential diagnosis

The patient exhibits many symptoms similar to Duchenne muscular dystrophy, a hereditary muscle disorder described by Guillaume Duchenne in 1858. These symptoms include a male sex, Duchenne/Trendelenburg gait, early disease onset, proximal muscle weakness, positive Tabouret sign, and flexor tendon shortening. However, there are some inconsistent features with Duchenne muscular dystrophy, such as normal creatine kinase levels and nondetected mutation on the *DMD* gene by *DMD* gene sequencing.

The goal of treatment was decreasing the muscle weakness progression of muscular dystrophy. The first-line treatment involves steroids (deflazacort or prednisone) combined with kinesiotherapie and ergotherapie, aimed at maintaining joint flexibility. In cases of muscular dystrophy with spinal deformities, the orthopedic doctor plays a significant role. In our patient, due to severe osteoporosis and vitamin D deficiency, we chose a bone resorption inhibitor (alendronate 70 mg weekly), supplemented with vitamin D and combined it with daily exercise to prevent joint stiffness and muscle atrophy from reduced mobility.

Discussions

According to the literature, congenital generalized lipodystrophy manifests in four subtypes, with types 1 and 2 being more prevalent, and types 3 and 4 being rare. Specifically, type 3 is uncommon. Karhan AN et al. conducted a study on a consanguineous family from Turkey with type 3 lipodystrophy due to a *CAV1* gene mutation encoding Caveolin-1. The patients ranged in age from 8 months to 18 years and exhibited insulin resistance, severe hypertriglyceridemia, and polycystic ovary syndrome. Osteoporosis and severe dysphagia causing swallowing difficulty were observed in two patients aged 15 and 18, without any cardiac manifestations [7]. A study by Lima JG in 2018 on bone density in patients with congenital generalized lipodystrophy type 2 found increased bone mass in the pelvis [9]. Our patient, along with those reported by Karhan AN, exhibited severe early-onset osteoporosis despite the phenotypic characteristics of type 3 lipodystrophy, including short stature, vitamin D deficiency, and osteoporosis, which are consistent with the reported clinical features.

In our study, the patient underwent a comprehensive medical history assessment, clinical examination, and evaluation of gait-related signs. He presented with a Duchenne/Trendelenburg gait and proximal muscle weakness. Combined with genetic analysis revealing a *CAV1* gene mutation with a heterozygous variant on chromosome 7, the patient was diagnosed with partial lipodystrophy with a heterozygous variant *CAV1* type 3. He has a short stature, measuring 141.2 cm in height

and weighing 34 kg, with a body mass index of 17.6, resembling the phenotype of different types of lipodystrophy as classified and described by author Iram Hussain in 2008 [10]. Disorder of stability in the vertical plane of the pelvis is observed, attributed to muscle weakness. The patient exhibits evident muscle weakness in assessment tests; he was unable to squat or stand up independently. Additionally, while walking, he displays a limp in the shoulders and pelvis. These signs indicate a combined shoulder and pelvic limp, resulting in a Duchenne/Trendelenburg gait.

The signs related to muscles include weakness in the proximal muscles (shoulder and hip joints), difficulty walking, inability to squat, and the inability to stand up independently, all suggestive of muscle-tendon damage. Additionally, Achilles tendon stiffness contributes to difficulty in walking. There is also difficulty in lifting the shoulders and maintaining balance, with challenges encountered in removing tight-fitting clothing. The presence of Trendelenburg sign while walking and difficulty standing up from a squatting position further suggests proximal muscle weakness. This musculoskeletal condition observed in our patient has not been described in the literature.

Congenital generalized lipodystrophy constitutes a rare group of disorders with diverse etiologies. It is typified by abnormal fat tissue distribution, involving either peripheral and subcutaneous fat loss or visceral fat accumulation. In a departure from typical presentations, our patient showed no subcutaneous or visceral fat based on DEXA imaging. Muscle weakness has been documented in various studies. For example, in patients with myotonic dystrophy type 1, muscle weakness has been linked to the extent of alternative splicing of exon 29 of the *CAV1* gene [11]. Furthermore, a study reported two siblings diagnosed with congenital generalized lipodystrophy and congenital muscular weakness without *CAV1* mutations or other common genes. Our patient displayed typical lipodystrophy characteristics of type 3, including short stature, vitamin D deficiency, and severe osteoporosis, aligning with documented clinical profiles. However, our patient also exhibited a Duchenne/Trendelenburg gait, indicating significant movement difficulty and an unsteady gait.

Conclusion and results

This is first case of congenital generalized lipodystrophy with *CAV1* gene mutation observed in Vietnam, significantly affecting the patient's motor function. The patient presents with a Duchenne/Trendelenburg gait, dysfunction of hand movement, a knee joint disorder, severe osteoporosis, and vitamin D deficiency. The diagnosis is established through genetic analysis conducted on both the patient and his daughter. In the future, early research on congenital generalized lipodystrophy is imperative to mitigate serious complications such as proximal muscle weakness, severe osteoporosis, and joint deformities, with the aim of minimizing motor dysfunction.

Declarations

Author contributions: Tam Thi Minh Mai, Ha Thi Vu coordinated the study. Huu Cong Nguyen, Anh Hong Vu, Trung Cong Nguyễn involved in clinical diagnosis and collected patient data. Tam Thi Minh Mai, Ha Thi Vu performed genetic analysis. Tam Thi Minh Mai, Ha Thi Vu interpreted the results and wrote the manuscript. All authors have read the manuscript and approved of the final version for publication.

Conflict of interest: The authors declare no conflict of interest.

Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments: The authors sincerely thank the valuable contributions of the patients and his family.

References

- Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins: a family of scaffolding proteins for organizing preassembled signaling complexes at the plasma membrane. *J Biol Chem.* 1998; 273: 5419–22.
- Garg A. Acquired and inherited lipodystrophies. *N Engl J Med.* 2004; 350: 1220–34.
- Jéru I. Genetics of lipodystrophy syndromes. *Presse Med.* 2021; 50: 104074.
- Adiyaman SC, von Schnurbein J, De Laffolie J, Hahn A, Siebert R, Wabitsch M, Kamrath C. Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution. *J Pediatr Endocrinol Metab.* 2022; 35: 946–52.
- Hussain I, Garg A. Lipodystrophy syndromes. *Endocrinol Metab Clin North Am.* 2016; 45: 783–97.
- Cao H, Alston L, Ruschman J, Hegele RA. Heterozygous CAV1 frameshift mutations in patients with atypical partial lipodystrophy and hypertriglyceridemia. *Lipids Health Dis.* 2008; 7: 3.
- Karhan AN, Zammouri J, Auclair M, Capel E, Apaydin FD, Ates F, Verpont MC, Magré J, Fève B, Lascols O, Usta Y, Jéru I, Vigouroux C. Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia. *Eur J Endocrinol.* 2021; 185: 841–54.
- Garg A, Kircher M, Del Campo M, Amato RS, Agarwal AK, University of Washington Center for Mendelian Genomics. Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. *Am J Med Genet A.* 2015; 167: 1796–806.
- Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Baracho MFP, Bandeira F, Capistrano L, Freire Neto FP, Jeronimo SMB. Bone density in patients with Berardinelli-Seip congenital lipodystrophy is higher in trabecular sites and in type 2 patients. *J Clin Densitom.* 2018; 21: 61–7.
- Hussain I, Garg A. Lipodystrophy syndromes. *Dermatol Clin.* 2008; 26: 569–79.
- Tang ZZ, Yarotskyy V, Wei L, Sobczak K, Nakamori M, Eichinger K, Moxley RT, Dirksen RT, Thornton CA. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channel. *Hum Mol Genet.* 2012; 21: 1312–24.